Where does Esteve Pharmaceuticals, S.A. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Esteve Pharmaceuticals, S.A. ranks #9,497 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Esteve Pharmaceuticals, S.A. hold?

Esteve Pharmaceuticals, S.A. holds 33 US utility patents granted between 2018 and 2025, spanning 10 technology areas.

What is Esteve Pharmaceuticals, S.A.'s Innovation Score?

Esteve Pharmaceuticals, S.A. has an Innovation Score of 36.2 out of 100 (top 47% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Esteve Pharmaceuticals, S.A. focus on?

Esteve Pharmaceuticals, S.A.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 30 patents, ranking #655 of 6,058 assignees active in that subclass. Grants appear in 10 CPC subclasses total.

Is Esteve Pharmaceuticals, S.A.'s patent grant rate increasing or decreasing?

Esteve Pharmaceuticals, S.A.'s recent grant velocity is +110% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Esteve Pharmaceuticals, S.A.'s patents?

Esteve Pharmaceuticals, S.A.'s patents average 17.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Esteve Pharmaceuticals, S.A. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Esteve Pharmaceuticals, S.A.

USPTO PatentsView assignee record - 33 granted patents across 10 technology areas, recorded in grant years 2018–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Esteve ranks #9,497 of 49,997 tracked US assignees by granted-patent volume, with 33 patents across 10 technology areas.

#9,497
of 49,997 US assignees by volume: Top 47%
by Innovation Score (36.2/100): 17.2
avg claims per patent: +110%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R9497 · Foreign Corporation #9,497 · 33 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 33 grants
UPPER-Q #9,497/49,997
PHOTO-FINISH Edico Genome
CPC-FOCUS A61P · 10 areas
INNOV-THIN 36.2/100
CLAIMS-RICH 17.2 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +110% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Edico Genome Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Esteve’s 36.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 12.2 pts (34%) Velocity 2.5 pts (7%) Breadth 11.2 pts (31%) Claim depth 10.3 pts (28%)

Qualcomm Incorporated · highest

85
Biosciences · near

36
Esteve Pharmaceuticals · this assignee

36
Kolcraft Enterprises · near

36
Totani · near

36
Qurio Holdings · near

36
3D Lighting… · lowest

7

What this shows Esteve's Innovation Score is 36.2/100 (top 47% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Esteve?

Each dot is one of Esteve’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Esteve’s own 17.2 claims/patent is ABOVE the 15.5 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Esteve vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Esteve's grants concentrate

Esteve Pharmaceuticals, S.A. is a focused PatentsView assignee: 10 CPC subclasses with 90.9% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (10 grants) versus a trough of 1 in 2023. By volume, Esteve sits between Electric Mirror, LLC and FEV Group GmbH.

Esteve's three-year grant acceleration

Esteve Pharmaceuticals, S.A. shows 7 grants in 2022–2024 against only 19 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Electric Mirror

33
Emerson Process M…

33
Epica Internation…

33
Eppendorf SE

33
Edico Genome

33
Eidgenössische Te…

33
Ethox Chemicals

33
FEV Group

33
Esteve Pharmaceut… ◀

33

What this shows Esteve holds 33 patents at rank #9,495, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Esteve

By rank, the assignees closest to #9,495 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Esteve's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Esteve, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Esteve ranks #655 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (36 here).

Kolcraft Enterprises, Inc. 36 Totani Corporation 36 Electronic Biosciences, Inc. 36 Qurio Holdings, Inc. 36

Esteve's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

36 Top 47% higher than 53% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Esteve Pharmaceuticals, S.A. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	5	15.2%
2019	5	15.2%
2020	10	30.3%
2021	4	12.1%
2022	4	12.1%
2023	1	3.0%
2024	2	6.1%
2025partial year	2	6.1%

Which technologies does Esteve Pharmaceuticals, S.A. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 30

C07D - Heterocyclic Compounds 26

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 8

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 7

C12Y - Enzymes 5

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 4

C07C - Acyclic OR Carbocyclic Compounds 3

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 2

C07K - Peptides 1

Y02A - Technologies FOR Adaptation TO Climate Change 1

Top 10 of 10 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Esteve Pharmaceuticals, S.A.'s patent record in context - here's where to go next.

Esteve Pharmaceuticals, S.A.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 90.9% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #9,497 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Esteve Pharmaceuticals, S.A. against Electric Mirror, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 36.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.